Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Transfection of embryo fibroblasts by a human ras oncogene does not convert them into tumour cells unless the fibroblasts are established and immortalized before transfection. The embryo fibroblasts become tumorigenic if a second oncogene such as a viral or cellular myc gene or the gene for the polyoma large-T antigen is introduced together with the ras gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16.”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“ras cooperates, however, with certain other oncogenic alterations to transform primary rodent cells (Land et al. 1983; Ruley 1983), including overexpression of c-Myc, dominant negative p53, D-type cyclins, and Cdc25A and -B, and loss of p53, p16, or IRF-1”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“In that setting, dysfunctional telomeres induced a strong cellular senescence phenotype in the emerging lymphomas resulting in potent suppression of lymphomagenesis.”
From Telomeres and telomerase in cancer (2010) · cites this paper as [93]
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Mutation selection and the natural history of cancer
Cairns, J. (1975) · Nature · doi:10.1038/255197a0 · Cited by 1,582
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis
Hayward, W. S., Neel, B. G., & Astrin, S. M. (1981) · Nature · doi:10.1038/290475a0 · Cited by 1,567
Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., & Leder, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7837 · Cited by 1,422
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Self-citationRuley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Self-citationDer, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
Research works printed but not linked: 9
- Berenblum, I. & Shubik, P. Br. J. Cancer 1, 388 (1947).
- Emmelot, P. & Scherer, E. Cancer Res. 37, 1702–1708 (1977).
- Crawford, B. D., Barrett, J. C. & Ts'o, P. O. P. Molec. cell. Biol. 3, 931–945 (1983). · doi:10.1128/mcb.3.5.931
- Murray, M. J. et al. Cell (in the press).
- Aaronson, S. A. & Todaro, G. J. J. Cell Biol. 72, 141–148 (1968).
- Perucho, M., Hanahan, D. & Wigler, M. Cell 22, 309–317 (1980). · DOI · Paper page
- Beard, J. W. in Viral Oncology (ed. Klein, G.) 55–88 (Raven, New York, 1980).
- Adams, J. M., Gerondakis, S., Webb, E., Corcoran, L. & Cory, S. Proc. natn. Acad. Sci. U.S.A. (in the press).
- Gross, L. Oncogenic viruses, 931 (Pergamon, Oxford, 1970).
Cited by
Items 201–300 of 1,010
N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma
Bernards, R., Dessain, S. K., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90509-x · Cited by 301
“…localization of their gene products and an ability of each to cooperate with ras oncogenes in the transformation of primary cells (Yee et al., 1983; Land et al., 1983; Ruley, 1983; Persson and Leder, 1984) Other evidence suggests that the c-myc protein, like Ela, can enhance the transcription of…”
InfluentialSelf-citationComparison of the in vitro transforming activities of human papillomavirus types.
Storey, A., Pim, D., Murray, A., Osborn, K., Banks, L., & Crawford, L. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03013.x · Cited by 302
Coming Full Circle—From Endless Complexity to Simplicity and Back Again
Weinberg, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.004 · Cited by 294
Self-citationSenescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
“Although tumour manifestation involves the activation of oncogenes and the inactivation of tumour suppressors, combined activation of two oncogenes, such as MYC and RAS, is sufficient to transform rodent cell”
BackgroundRegulation of the Human hsp70 Promoter by p53
Agoff, S. N., Hou, J., Linzer, D. I., & Wu, B. (1993) · Science · doi:10.1126/science.8418500 · Cited by 292
Kinoshita, T., Yokota, T., Arai, K., & Miyajima, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07000.x · Cited by 298
Phospholipase D in cell proliferation and cancer.
Foster, D. A., & Xu, L. (2003) · PubMed · Cited by 334
Functional Specificity of Ras Isoforms: So Similar but So Different
Castellano, E., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911408081 · Cited by 273
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
“These include, for example, mutations allowing constitutive mitogenic signaling, mutations that allow cells to overcome restrictions on cell cycle checkpoints, or mutations that allow cells to overcome programmed cell death (Land et al., 1983).”
BackgroundIntragenic pausing and anti-sense transcription within the murine c-myc locus.
Nepveu, A., & Marcu, K. B. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04580.x · Cited by 309
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 275
BRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“More than two decades ago, it was observed that mutationally activated RAS, introduced in untransformed fibroblasts, induced cell cycle arrest rather than oncogenic transformation (Land et al., 1983; Franza et al., 1986).”
BackgroundDonehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., & Varmus, H. E. (1995) · Genes & Development · doi:10.1101/gad.9.7.882 · Cited by 276
The p16INK4a-RB pathway : molecular link between cellular senescence and tumor suppression
Ohtani, N., Yamakoshi, K., Takahashi, A., & Hara, E. (2004) · The Journal of Medical Investigation · doi:10.2152/jmi.51.146 · Cited by 276
Ras1 Promotes Cellular Growth in the Drosophila Wing
Prober, D. A., & Edgar, B. A. (2000) · Cell · doi:10.1016/s0092-8674(00)80679-0 · Cited by 275
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Ding, H., Roncari, L., Shannon, P. T., Wu, X., Lau, N. C., Karásková, J., Gutmann, D. H., Squire, J. A., Nagy, A., & Guha, A. (2001) · PubMed · Cited by 271
E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor.
Hiebert, S. W., Lipp, M., & Nevins, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3594 · Cited by 274
Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture
Schwab, M., Varmus, H. E., & Bishop, J. M. (1985) · Nature · doi:10.1038/316160a0 · Cited by 288
Zhang, X., Morham, S. G., Langenbach, R., & Young, D. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.4.451 · Cited by 273
“The expression of a mutant ras gene usually does not by itself lead to a transformed phenotype in primary cultured cells; additional mutations in other protooncogenes such as c-myc, or inactivation of tumor suppressor genes such as p53, are required to achieve a full malignant transformation (21).”
BackgroundBehavior of myc and ras oncogenes in transformation of rat embryo fibroblasts.
Land, H., Chen, A. C., Morgenstern, J. P., Parada, L. F., & Weinberg, R. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.1917 · Cited by 266
“In previous reports, we and others have described experiments which suggested that multiple oncogenes are required to mediate the transformation of normal cells into tumorigenic cells (8, 13, 14, 16, 18, 20, 23, 26, 32, 35-37, 50).”
BackgroundMethodResultInfluentialSelf-citationOne- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes.
Fusco, A., Berlingieri, M. T., Di Fiore, P. P., Portella, G., Grieco, M., & Vecchio, G. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.9.3365 · Cited by 270
RetractedPapa, S. (1996) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(96)00077-1 · Cited by 266
Chemical Carcinogenesis: From Animal Models To Molecular Models In One Decade
(1988) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60434-0 · Cited by 267
The metabolic defect of methionine dependence occurs frequently in human tumor cell lines
Mecham, J. O., Rowitch, D., Wallace, C. D., Stern, P. H., & Hoffman, R. M. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91218-4 · Cited by 247
MYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
“In agreement with previous results obtained in MEFs, Eµ-MYC derived pre-B cells showed high rates of apoptosis and increased ARF levels, while p53 levels remained constant when compared to control cells.”
BackgroundPancreatic neoplasia induced by ras expression in acinar cells of transgenic mice
Quaife, C. J., Pinkert, C. A., Ornitz, D. M., Palmiter, R. D., & Brinster, R. L. (1987) · Cell · doi:10.1016/0092-8674(87)90710-0 · Cited by 262
Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa.
Sakamoto, H., Mori, M., Taira, M., Yoshida, T., Matsukawa, S., Shimizu, K., Sekiguchi, M., Terada, M., & Sugimura, T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3997 · Cited by 268
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90100-7 · Cited by 265
Stanbridge, E. J. (1990) · Annual Review of Genetics · doi:10.1146/annurev.ge.24.120190.003151 · Cited by 259
Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., & Hung, M. (1993) · PubMed · Cited by 284
Growth-factor-dependent mitogenesis requires two distinct phases of signalling
Jones, S. M., & Kazlauskas, A. (2001) · Nature Cell Biology · doi:10.1038/35055073 · Cited by 262
“Time after intial PDGF administration (h) PDGF (0) + PDGF (12) PDGF (0) + PDGF (10) 10 –1 2 12 –1 4 14 –1 6 16 –1 8 18 –2 0 20 –2 2 22 –2 4 24 –2 6 26 –2 8 28 –3 0 30 –3 2 32 –3 4 34 –3 6 36 –3 8 38 –4 0 40 –4 2 PDGF (30) PDGF (30) + PDGF (8) PDGF Collection”
Gay, S., Gay, R. E., & Koopman, W. J. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.suppl_1.s39 · Cited by 262
Genetic pathways in colorectal and other cancers
Ilyas, M., Straub, J., Tomlinson, I. P. M., & Bodmer, W. F. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00431-6 · Cited by 257
Nuclear Localization and DNA Binding Properties of a Protein Expressed by Human c- myc Oncogene
Persson, H., & Leder, P. (1984) · Science · doi:10.1126/science.6463648 · Cited by 281
Akagi, T., Sasai, K., & Hanafusa, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834876100 · Cited by 260
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer
Anand, N., Murthy, S., Amann, G., Wernick, M., Porter, L. A., Cukier, I. H., Collins, C., Gray, J. W., Diebold, J., Demetrick, D. J., et al. (2002) · Nature Genetics · doi:10.1038/ng904 · Cited by 255
“The ability to form foci in cell culture is a marker of cell transformation and is considered one of the general properties of an oncogene such as RAS”
BackgroundActivation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus
Hayday, A. C., Gillies, S. D., Saito, H., Wood, C., Wiman, K., Hayward, W. S., & Tonegawa, S. (1984) · Nature · doi:10.1038/307334a0 · Cited by 266
LINDSAYWILLIAMS, R. (1988) · Cell · doi:10.1016/0092-8674(88)90536-3 · Cited by 259
The cell-cell channel in the control of growth
Loewenstein, W. R., & Rose, B. (1992) · Seminars in Cell Biology · doi:10.1016/s1043-4682(10)80008-x · Cited by 250
Human N-myc is closely related in organization and nucleotide sequence to c-myc
Kohl, N. E., Legouy, E., DePinho, R. A., Nisen, P. D., Smith, R. K., Gee, C. E., & Alt, F. W. (1986) · Nature · doi:10.1038/319073a0 · Cited by 274
Model for the genetic evolution of human solid tumors.
Shackney, S. E., Smith, C., Miller, B. W., Burholt, D. R., Murtha, K., Giles, H. R., Ketterer, D. M., & Pollice, A. A. (1989) · PubMed · Cited by 252
RAS pathways to cell cycle control and cell transformation
Pellicer, A. (1998) · Frontiers in Bioscience · doi:10.2741/a331 · Cited by 248
c-myc down-regulates class I HLA expression in human melanomas.
Versteeg, R., Noordermeer, I. A., Krüse-Wolters, M., Ruiter, D. J., & Schrier, P. I. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02909.x · Cited by 252
Packham, G., & Cleveland, J. L. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)00015-t · Cited by 245
Lang, R. A., Metcalf, D., Gough, N. M., Dunn, A. R., & Gonda, T. J. (1985) · Cell · doi:10.1016/0092-8674(85)90182-5 · Cited by 253
Gene Amplification of c- myc and N- myc in Small Cell Carcinoma of the Lung
Wong, A. J., Ruppert, J. M., Eggleston, J., Hamilton, S. R., Baylin, S. B., & Vogelstein, B. (1986) · Science · doi:10.1126/science.3014659 · Cited by 251
Chi, S., Kitanaka, C., Noguchi, K., Mochizuki, T., Nagashima, Y., Shirouzu, M., Fujita, H., Yoshida, M., Chen, W., Asai, A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202538 · Cited by 245
“B, and loss of p53, p16, or IRF-1 (Land et al., 1983; Lovec et al., 1994; Tanaka et al., 1994; Galaktionov et al., 1995; Serrano et al., 1996).”
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours
Fourel, G., Trepo, C., Bougueleret, L., Henglein, B., Ponzetto, A., Tiollais, P., & Buendia, M.-A. (1990) · Nature · doi:10.1038/347294a0 · Cited by 249
Wolf, D., Harris, N., & Rotter, V. (1984) · Cell · doi:10.1016/0092-8674(84)90532-4 · Cited by 249
MYC in Oncogenesis and as a Target for Cancer Therapies
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07006-5 · Cited by 242
A Turning Point in Cancer Research: Sequencing the Human Genome
Dulbecco, R. (1986) · Science · doi:10.1126/science.3945817 · Cited by 235
Fluorescence microphotolysis to measure nucleocytoplasmic transport and intracellular mobility
Peters, R. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(86)90003-1 · Cited by 246
Hurlin, P. J., Quéva, C., & Eisenman, R. N. (1997) · Genes & Development · doi:10.1101/gad.11.1.44 · Cited by 245
He, Z., Jiang, J., Kokkinaki, M., Golestaneh, N., Hofmann, M.-C., & Dym, M. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0436 · Cited by 242
Schütte, J., Minna, J. D., & Birrer, M. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2257 · Cited by 250
Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis.
Packham, G., & Cleveland, J. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.5741 · Cited by 245
“Both c-myc and ODC cooperate with activated ras in transformation of fibroblasts (19, 24, 25, 39), and as with c-Myc (18), ODC is required for entry into the S phase of the cell cycle (8, 30a).”
BackgroundRegulation of heat shock protein 70 gene expression by c-myc
Kingston, R. E., Baldwin, A. S., & Sharp, P. A. (1984) · Nature · doi:10.1038/312280a0 · Cited by 258
Jones, R. M., Branda, J., Johnston, K. A., Polymenis, M., Gadd, M., Rustgi, A., Callanan, L., & Schmidt, E. V. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4754 · Cited by 237
Brown, K., Quintanilla, M., Ramsden, M., Kerr, I. B., Young, S., & Balmain, A. (1986) · Cell · doi:10.1016/0092-8674(86)90665-3 · Cited by 245
“, 1985), in contrast to experiments without enhancers where two cooperating oncogenes are required (Land et al., 1983; Ruley, 1983; Newbold and Overell, 1983).”
BackgroundThinking about genetic redundancy
Thomas, J. H. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90140-d · Cited by 239
The oncogenic potential of Pax genes.
Maulbecker, C. C., & Gruss, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05890.x · Cited by 241
Negative autoregulation of c-myc transcription.
Penn, L. J., Brooks, M. W., Laufer, E. M., & Land, H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08217.x · Cited by 244
Self-citationCraig, A. M., Smith, J. H., & Denhardt, D. T. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60584-8 · Cited by 238
Mutations in N-ras predominate in acute myeloid leukemia
Bos, J., Verlaan-de Vries, M., van der Eb, A., Janssen, J., Delwel, R., Lowenberg, B., & Colly, L. (1987) · Blood · doi:10.1182/blood.v69.4.1237.1237 · Cited by 235
Zhao, J. J., Cheng, H., Jia, S., Wang, L., Gjoerup, O. V., Mikami, A., & Roberts, T. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607899103 · Cited by 224
Structural and functional aspects of the multiplicity of Neu differentiation factors.
Wen, D., Suggs, S. V., Karunagaran, D., Liu, N., Cupples, R. L., Luo, Y., Janssen, A. M., Ben-Baruch, N., Trollinger, D. B., & Jacobsen, V. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1909 · Cited by 234
“Rat-1-EJ cells, generated by transfection of the human EJ ras oncogene into Rat-1 fibroblasts, were previously described (19, 30).”
Methodmyc Family Oncogenes in the Development of Normal and Neoplastic Cells
(1991) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60994-x · Cited by 233
Amson, R., Sigaux, F., Przedborski, S., Flandrin, G., Givol, D., & Telerman, A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8857 · Cited by 231
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation
Hydbring, P., Bahram, F., Su, Y., Tronnersjö, S., Högstrand, K., von der Lehr, N., Sharifi, H. R., Lilischkis, R., Hein, N., Wu, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900121106 · Cited by 225
“M than two decades ago, Weinberg and co-workers (1) showed that no more than two activated oncogenes, c-myc and H-ras, are sufficient to transform primary rodent cells into cancerous cells.”
BackgroundPelengaris, S., & Khan, M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00294-7 · Cited by 225
Moran, E., Zerler, B., Harrison, T. M., & Mathews, M. B. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.10.3470 · Cited by 231
“The c-myc oncogene contains a similar stretch of acidic amino acids (40), and it has been shown that the myc oncogene, like ElA, will complement the ras oncogene in transforming primary cells (30, 43).”
BackgroundSuda, K., Tomizawa, K., & Mitsudomi, T. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9209-4 · Cited by 222
Kottakis, F., Polytarchou, C., Foltopoulou, P., Sanidas, I., Kampranis, S. C., & Tsichlis, P. N. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.020 · Cited by 224
“Since earlier observations provided evidence for a link between cell proliferation/soft agar growth and oncogenicity (Land et al., 1983), we interpret the preceding data to suggest a role of the NDY1miR-101-EZH2 pathway in oncogenesis.”
Expression of Gene rrg Is Associated with Reversion of NIH 3Tt3 Transformed by LTR-c-H- ras
Contente, S., Kenyon, K., Rimoldi, D., & Friedman, R. M. (1990) · Science · doi:10.1126/science.1697103 · Cited by 221
Dumble, M. L., Croager, E. J., Yeoh, G. C. T., & Quail, E. A. (2002) · Carcinogenesis · doi:10.1093/carcin/23.3.435 · Cited by 222
“Recent studies in primary embryonic fibroblasts suggest the cooperation of at least two oncogenes is necessary for a cell to be tumorigenic ( 10 ).”
BackgroundPozzatti, R., Vogel, J., & Jay, G. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.1.413 · Cited by 217
“oncogenes to transform primary rodent cells in culture (2, 13, 24, 26).”
BackgroundThor, A., Hand, P. H., Wunderlich, D., Caruso, A., Muraro, R., & Schlom, J. (1984) · Nature · doi:10.1038/311562a0 · Cited by 223
Andres, A. C., Schönenberger, C. A., Groner, B., Hennighausen, L., LeMeur, M., & Gerlinger, P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1299 · Cited by 225
Two regions of the adenovirus early region 1A proteins are required for transformation
Whyte, P., Ruley, H. E., & Harlow, E. (1988) · Journal of Virology · doi:10.1128/jvi.62.1.257-265.1988 · Cited by 226
Myc‐induced proliferation and transformation require Akt‐mediated phosphorylation of FoxO proteins
Bouchard, C., Marquardt, J., Brás, A., Medema, R. H., & Eilers, M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600279 · Cited by 210
“Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins”
BackgroundMaher, P. A., Pasquale, E. B., Wang, J. Y., & Singer, S. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6576 · Cited by 219
Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression.
Moshier, J. A., Dosescu, J., Skunca, M., & Luk, G. D. (1993) · PubMed · Cited by 232
SIRT3 regulates progression and development of diseases of aging
McDonnell, E., Peterson, B. S., Bomze, H. M., & Hirschey, M. D. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.06.001 · Cited by 217
Lehmann, J., Holzmann, B., Breitbart, E. W., Schmiegelow, P., Riethmüller, G., & Johnson, J. P. (1987) · PubMed · Cited by 217
Neoplastic Transformation of Human Epidermal Keratinocytes by AD12-SV40 and Kirsten Sarcoma Viruses
Rhim, J. S., Jay, G., Arnstein, P., Price, F. M., Sanford, K. K., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2579430 · Cited by 216
Sears, R., Ohtani, K., & Nevins, J. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5227 · Cited by 214
“Second, a variety of studies have suggested a similarity between the action of adenovirus E1A, which activates E2F, and Myc, particularly with respect to the oncogenic activity of the two proteins (39, 48, 49).”
BackgroundRidley, A. J., Paterson, H. F., Noble, M., & Land, H. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02990.x · Cited by 216
Self-citationBoukamp, P., Stanbridge, E. J., Foo, D., Cerutti, P., & Fusenig, N. E. (1990) · PubMed · Cited by 212
Transcription of the human hsp70 gene is induced by serum stimulation.
Wu, B. J., & Morimoto, R. I. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6070 · Cited by 221
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc–induced apoptosis
You, Z., Saims, D., Chen, S., Zhang, Z., Guttridge, D. C., Guan, K.-L., MacDougald, O. A., Brown, A. M. C., Evan, G., Kitajewski, J., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201110 · Cited by 211
“tion (Land et al., 1982; Bissonnette et al., 1992; Cory et al., 1999), an assessment was made whether Wnt-1 coordinated with c-Myc in oncogenic transformation by inhibiting apoptosis.”
BackgroundMethodDissecting Multistep Tumorigenesis in Transgenic Mice
Hanahan, D. (1988) · Annual Review of Genetics · doi:10.1146/annurev.ge.22.120188.002403 · Cited by 211
Diet, nutrition, and cancer: An update on a controversial relationship
Purtilo, D. T., & Cohen, S. M. (1985) · Postgraduate Medicine · doi:10.1080/00325481.1985.11699066 · Cited by 208
Piechaczyk, M., Yang, J.-Q., Blanchard, J.-M., Jeanteur, P., & Marcu, K. B. (1985) · Cell · doi:10.1016/0092-8674(85)90116-3 · Cited by 220
The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation.
Olson, E. N., Spizz, G., & Tainsky, M. A. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.6.2104 · Cited by 210
“Plasmids used for measurement of individual mRNAs were as follows: MCK, a 775-base-pair SmaI-PvuI fragment from a canine MCK cDNA (43); GAPDH, a 1,650-base-pair HhaI fragment from a chicken GAPDH cDNA (9); c-myc, a 2,500-base-pair HindIII-XbaI fragment from pSVc-myc-1, containing exons 2 and 3 of mouse c-myc (25).”
MethodAnticancer Activity of the Cholesterol Exporter ABCA1 Gene
Smith, B., & Land, H. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.011 · Cited by 204
“We developed a strategy to identify such genes based on the notion that malignant cell transformation is a highly cooperative process (Hahn et al., 1999; Land et al., 1983) and involves synergistic regulation of nonmutant genes and proteins downstream of oncogenic mutations (Lloyd et al.”
Self-citationAdeno-Associated Viruses: An Update
Berns, K. I., & Bohenzky, R. A. (1987) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60479-0 · Cited by 207
Chen, H., Ruiz, P. D., McKimpson, W. M., Novikov, L., Kitsis, R. N., & Gamble, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.011 · Cited by 205
“In the absence of additional genomic insults, activation of an oncogene is often insufficient to transform a cell (Land et al., 1983).”
Sklar, J., Cleary, M. L., Thielemans, K., Gralow, J., Warnke, R., & Levy, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198407053110104 · Cited by 206
Is cell competition relevant to cancer?
Moreno, E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2252 · Cited by 202
“As described above, MYC and genes of the Hippo pathway stimulate cell super-competition, but, on the contrary, there are old observations that suggest that surrounding normal cells can suppress the proliferation of cells transformed by some oncogenes, such as activated HRAS”
Background
Metadata
- Authors
- Land, H., Parada, L. F., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Venue
- Nature
- Published
- 1983-08
- Volume
- 304
- Issue
- 5927
- Pages
- 596-602
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1989009382
- Cited by
- 2,804
- References
- 56
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 22 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 22 · 2019: 36 · 2018: 17 · 2017: 23 · 2016: 24 · 2015: 39 · 2014: 27 · 2013: 30 · 2012: 37
- FWCI
- 96.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- embryonic fibroblasts, oncogene cooperation, oncogenic Ras, MYC gene, polyomavirus large T antigen, cell immortalization, transfection
- MeSH terms
- Animals, Antigens, Viral, Antigens, Viral, Tumor, Cell Line, Cell Transformation, Viral, Cells, Cultured, Fibroblasts, Gene Expression Regulation, Genes, Viral, Genetic Complementation Test, Oncogenes, Phenotype, Polyomavirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.